ArticleNucleic acids research2026
Development of a tetracycline-inducible programmed ribosomal frameshifting platform for sensitive regulation of mammalian gene expression.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Developing engineered genetic switches that can respond to specific stimuli in mammalian systems has great potential to advance next-generation therapies. This study introduces a novel tetracycline-inducible artificial riboswitch that regulates gene expression at the translational level via a modified -1 programmed ribosomal frameshifting (-1 PRF) platform. Our dose-response analysis reveals an EC50 of 0.41 μM, indicating exceptional sensitivity compared to other tetracycline-dependent artificial riboswitches developed for mammalian applications. By varying the precise spacing and composition of the tetracycline aptamer as the stimulatory structure on the -1 PRF platform, a series of switches has been constructed that enable robust induction of gene expression upon ligand addition. To attain a translational gene control platform with broader applicability, we developed a concept that allows it to be integrated upstream of a gene of interest (GOI), enabling precise control without requiring extensive re-engineering and expressing the GOI as a fusion protein. We validate the platform's effectiveness in several genetic contexts, confirming its modularity. As optimization efforts continue to develop artificial riboswitches with optimized properties in mammalian systems, our findings contribute to the development of highly sensitive and efficient regulatory devices with beneficial characteristics, such as reversibility, modularity, and compatibility with RNA-based delivery therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.